01.06.2009 | Letter to the Editor
Pantalone et al.: The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis
Erschienen in: Acta Diabetologica | Ausgabe 2/2009
Einloggen, um Zugang zu erhalten